J&J prevails against Boston in stent litigation with $1.73bn settlement
This article was originally published in Clinica
Executive Summary
Johnson & Johnson has received a boost in its ongoing tussle for the top spot in the drug-eluting stent market after it prevailed in three long-standing lawsuits involving rival Boston Scientific.